THE APPLICATION OF ATP-SENSITIVE POTASSIUM CHANNELS^ OPENER-NICORANDIL IN TREATMENT OF CORONARY HEART DISEASE



Cite item

Full Text

Abstract

This review describes the results of the research works, which studied anti-ischemic and cardioprotective properties of ATP-sensitive potassium channels' opener - nicorandil that improves coronary blood flow in coronary heart disease (CHD). The therapeutic potential of nicorandil indicates the availability of its using for the treatment of not only chronic, but also acute forms of CHD and arrhythmias, which should be confirmed by the results of additional clinical studies.

About the authors

E M Nifontov

Pavlov Saint-Petersburg State Medical University

Ya V Andreev

Federal Almazov Medical Research Centre

References

  1. ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology European Heart Journal // Eur. Heart J. - 2013. - Vol. 34. - P. 2949-3003.
  2. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil // Cardiovasc. Drugs Ther. - 1990. - Vol. 4. - № 4. - P. 1075-1088.
  3. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators // Am. J. Cardiol. -1989. - Vol. 63. -№ 21. - P. 18-24.
  4. Kukovetz W. R., Holzmann S., Poch G. Molecular mechanism of action of nicorandil // J. Cardiovasc. Pharmacol. - 1992. - Vol. 20. - Suppl 3. - P. 1-7.
  5. Бадриддинова Л. Ю., Юргель Н. В., Кукес В. Г., Павлова Л. И. Фармакодинамика и клиническая эффективность никорандила // Клиническая фармакология и терапия 2009. -№ 6. - С. 124-125.
  6. Shojima T., Hayashida N., Nishi A., Takagi K., Hori H., Yoshikawa K., Aoyagi S. Effects of nicorandil preconditioning on membrane dystrophin // Eur. J. Cardiothorac. Surg. -2006. -Vol. 30. - P. 472-479.
  7. Fox К., Garcia М. A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology // Eur. Heart J. - 2006. - Vol. 27. - № 11. - P. 1341-1381.
  8. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Пересмотр 2008 //Кар-диоваскулярная терапия и профилактика. - 2008. - Приложение 4. - 40 с.
  9. Announcement of supplemental approval of indication of Sigmart® Injection, a treatment drug for unstable angina pectoris, 23/10/2007. - http://www.chugaipharm.co.jp/english/news/detail/20071023000000.html. - Последнее посещение сайта 28.10.14.
  10. Patel D. J., Purcell H. J., Fox K. M. Cardioprotection by opening of the K (ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization // Eur. Heart J. - 1999. - Vol. 20. - P. 51-57.
  11. Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reper-fusion treatment for acute myocardial infarction (J-WIND): two randomised trials // Lancet. - 2007. - Vol. 370. - P. 1483-93.
  12. Fox K., Ford I., Steg, P. G., Tendera, M. and Ferrari R. Ivabradine for patients with stablecoronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised,double-blind, placebo-controlled trial //Lancet. - 2008. - Vol. 372. - № 9641. - P. 807-816.
  13. Chaitman B. R., Pepine C. J., Parker J. O. et al. for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina // JAMA. - 2004. - Vol. 291. - Р. 309-316.
  14. Chaitman B. R., Skettino S. L., Parker J. O. et al. Anti-ischemic effects and long-term survival during ranola-zine monotherapy in patients with chronic severe angina //J. Am. Coll. Cardiol. - 2004. - Vol. 43. - № 8. - P. 1375-1382.
  15. Stone P. H., Gratsiansky N. A., Blokhin A. et al. for the ERICA investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial //J. Am. Coll. Cardiol. - 2006. - Vol. 48. - P. 566-575.
  16. Wilson S. R., Scirica B. M., Braunwald E. еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial //J. Am. Coll. Cardiol. - 2009. - Vol. 53. - № 17. - P. 1510-1516.
  17. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial // Lancet. - 2002. - Vol. 359. - P. 1269-1275.
  18. IONA Study Group. Impact of nicorandil in angina: subgroup analyses // Heart. -2004. - Vol. 90. - № 12. - P. 1427-30.
  19. The Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan: The Japanese Coronary Artery Disease Study (The JCAD Study) // Circ. J. -2006. - Vol. 70. - P. 1256-1262.
  20. Сизова Ж. M., Ших Е. В., Захарова В. Л., Смирнова Е. В. Современная фармакотерапия стабильной стенокардии: возможности и перспективы применения никорандила // Рациональная фармакотерапия в кардиологии. - 2010. - Т. 6. - № 4. - С. 455-460.
  21. Zhu W. L. et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China // Circ. J. - 2007. - Vol. 71. - № 6. - P. 826-833.
  22. Izumiya Y., Kojima S., Kojima S. et al. Longterm use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. - 2011. - P. 415-421.
  23. Ishibashi Y. et al. Effects of long-term nicorandil administration on endothelial function. inflammation, and oxidative stress in patients without coronary artery disease // J. Cardiovasc. Pharmacol. - 2008. - Vol. 51. - № 3. - P. 311.
  24. Kusama Y., Kodani E., Nakagomi A., Otsuka T., Atarashi H., Kishida H., Mizuno K. Variant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and management //J. Nippon. Med. Sch. - 2011. - Vol. 78. - № 1. - P. 4-12.
  25. Lablanche J. M., Bauters C., McFadden E. P., Quandalle P., Bertrand M. E. Service de Cardiologie B et Hemodynamique, Hopital Cardiologique, Lille, France. Potassium channel activators in vasospastic angina // Eur. Heart J. - 1993. - Vol. 14. - Suppl B. - P. 22-24.
  26. Kishida H., Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris // Clin. Pharmacol. Ther. - 1987. - Vol. 42. - № 2. - P. 166-174.
  27. Lee K. H., Kim S. H., Lim H. E. et al. Effectiveness of intravenous administration of nicorandil in a patient with variant angina refractory to continuous intravenous nitroglycerin // Int. J. Cardiol. - 2007. - Vol. 120. - № 1. - P. 9-12.
  28. Ohno Y., Minatoguchi S., Uno Y. et al. Nicorandil reduces myocardial infarct size by opening the KATP channel in rabbits // Int. J. Cardiol. - 1997. - Vol. 62. - P. 181-190.
  29. Crover G. J. Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Can. Crover G. J. Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion // Can. J. Physiol. Pharmacol. - 1997. - Vol. 75. - P. 309-315.
  30. Lee Н. С., An S. G., Choi J. H. et al. Effect of intra-coronary nicorandil administration prior to «perfusion in acute ST segment elevation myocardial infarction // Circ. J. 2008. - Vol. 72. - P. 1425-1429.
  31. Ren Z., Yang Q., Floten H. S., Furnaiy A. P., Yim A. P., He G. W. ATP-sensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery // Ann. Thorac. Suig. - 2001. - Vol. 71. - P. 642-647.
  32. Lim S. Y., Bae E. H., Jeong M. H. et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention // Circ. J. - 2004. - Vol. 68. - № 10. - P. 928-932.
  33. Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials // Lancet. - 2007. - Vol. 370. - P. 1483-1493.
  34. Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. - 2012. - Vol. 59. - № 1. - P. 14-21.
  35. Iwakura K., Ito H., Okamura A., Koyama Y. et al. Nicorandil treatment in patients with acute myocardial infarction: A meta-analysis // Circ. J. - 2009. - Vol. 73. - P. 925-931.
  36. Iliodromitis E. K., Cokkinos P., Zoga A. et al. Oral nicorandil recaptures the waned protection from preconditioning in vivo // Br. J. Pharmacol. - 2003. - Vol. 38. - № 6. - P. 1101-1106.
  37. Lee T. M., Su S. F., Chou T. F. et al. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty // Circulation 2002. - Vol. 105. - № 3. - P. 334-340.
  38. Rezkalla S. H, Kloner R. A. Preconditioning in humans // Heart Fail Rev. - 2007. - Vol. 12. - № 3-4. - P. 201-206.
  39. Sanada S., Node K., Asanuma H. et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase // J. Am. Coll. Cardiol. - 2002. - Vol. 40. - № 5. - Р. 991-997.
  40. Hara H., Horinaka S., Yabe A., Yagi H., Tsuboko Y., Yoshida K., lemura T, Matsuoka H. J. Suppressive effect of nicorandil in ventricular arrhythmias after reperfusion therapy in patients with acute myocardial infarction // Cardiol. - 2007. - Vol. 49. - № 3. - P. 135-141.
  41. Ueda H., Nakayama Y., Tsumura K, Yoshimaru K., Hayashi T, Yoshikawa J. Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction // Can. J. Cardiol. - 2004. - Vol. 20. - № 6. - P. 625-629.
  42. Vegh A., Gyorgyi K., Papp J. G., Sakai K., Parratt J. R. Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia // Naunyn Schmiedebergs Arch. Pharmacol. - 2002. - Vol. 366. - № 6. - P. 522-527.
  43. Horinaka S., Kobayashi N., Yabe A., Asakawa H., Yagi H., Mori Y. et al. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction // Cardiovasc. Drugs Ther. - 2004. - Vol. 18. - P. 13-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Nifontov E.M., Andreev Y.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies